Replicative minicircle vectors with improved expression
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention relates to the production and use of covalently closed circular (ccc) recombinant DNA molecules such as plasmids, cosmids, bacterial artificial chromosomes (BACs), bacteriophages, viral vectors and hybrids thereof, and more particularly to vector modifications that improve expression of said DNA molecules.
Core Innovation
The invention provides eukaryotic replicative minicircle expression vectors comprising a eukaryotic region encoding a gene of interest with an intron, a bacterial replication origin, and an RNA selectable marker. A spacer region linking the 5′ and 3′ ends of the eukaryotic region is less than 500 basepairs in length. Disclosed replication origins include R6K, ColE2-P9, pUC, and minimal pUC origins, with the origin and marker optionally embedded in an intron or a 3′ untranslated region.
The constructs support gene expression and bacterial-cell propagation without protein-based selection markers while maintaining generally accurate splicing of intronic origin and marker insertions. In addition, the vectors achieve fermentation yields of 184–745 mg/L and demonstrate improved in vivo transgene expression across multiple vector configurations. These vectors are simpler to manufacture than conventional minicircles while retaining a spacer under 500 basepairs.
Claims Coverage
The independent claims cover three inventive features relating to methods of constructing a eukaryotic replicative minicircle expression vector and the vector construct itself.
Vector construction and gene expression in a eukaryotic cell
Independent claim 1 covers a method of constructing a eukaryotic replicative minicircle expression vector comprising a eukaryotic region encoding a gene of interest with an intron having a 5′ splice donor and a 3′ acceptor branch site, an R6K or ColE2-P9 bacterial replication origin, an RNA selectable marker, and a spacer region less than 500 basepairs in length, further covering expression of the gene of interest in a target eukaryotic cell.
Vector construction and bacterial-cell propagation
Independent claim 6 covers a method of constructing a eukaryotic replicative minicircle expression vector comprising a eukaryotic region encoding a gene of interest with an intron having a 5′ splice donor and a 3′ acceptor branch site, an R6K or ColE2-P9 bacterial replication origin, an RNA selectable marker, and a spacer region less than 500 basepairs in length, alongside bacterial-cell selection and propagation in culture.
Eukaryotic replicative minicircle expression vector
Independent claim 11 covers a vector comprising a eukaryotic region encoding a gene of interest and comprising an intron with a 5′ splice donor and a 3′ acceptor branch site, a bacterial replication origin selected from R6K and ColE2-P9, an RNA selectable marker, and a spacer region less than 500 basepairs in length linking the 5′ and 3′ ends of the eukaryotic region.
The independent claims cover vector construction for eukaryotic gene expression, bacterial-cell propagation, and the physical vector construct, each incorporating an intron, a bacterial replication origin, an RNA selectable marker, and a short spacer.
Stated Advantages
The vectors are simpler to manufacture than conventional minicircles.
The vectors provide improved in vivo transgene expression across several vector configurations.
The vectors provide functional intronic origin and marker insertions with generally accurate splicing.
The vectors enable high-yield manufacture, with fermentation yields of 184–745 mg/L.
The vector supports bacterial propagation without protein-based selection markers.
Documented Applications
Expression of a gene of interest from the eukaryotic replicative minicircle expression vector in a target eukaryotic cell or an organism comprising that cell.
Construction and propagation of eukaryotic replicative minicircle expression vectors in bacterial cells associated with an RNA selectable marker, including selection and propagation of transformed cells.
Gene therapy.
Genetic immunization.
Interferon therapy.
Interested in licensing this patent?